Evidence map›Paper›PMID 42088550›Full record

ArticleInternational journal of cardiology. Heart & vasculature2026

Oral P2Y

Chiara Schaffner, Yanick Spahr, Alessandro Spirito, Gregorio Tersalvi, Irena Majcen, Firat Erdogan, Yuan Zhi, Armin Spahr, Thomas Seiler, Adrian Attinger and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chiara SchaffnerCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Yanick SpahrCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Alessandro SpiritoCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Gregorio TersalviDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Irena MajcenCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Firat ErdoganCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Yuan ZhiCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Armin SpahrCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Thomas SeilerDepartment of Cardiology, Inselspital Berne, Berne, Switzerland.
Adrian AttingerCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Florim CuculiCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.
Matthias BossardCardiology Division, Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oral P2Y Objective: Comparison of outcomes in patients undergoing Impella-supported PCI receiving oral P2Y Methods: We analyzed consecutive patients managed at a Swiss tertiary cardiology facility who underwent Impella-supported PCI. Patients received either (1) oral P2Y Results: Among 295 patients, 201 received oral P2Y Conclusion: In Impella-supported PCI, cangrelor was associated with no statistically significant differences in outcomes compared to oral P2Y

Indexed as

Antiplatelet therapyCangrelorCardiogenic shockMyocardial infarctionPCI

Identifiers

PMID42088550
PMCPMC13137070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.